Shenzhen Salubris Pharmaceuticals Reports First Half Results with Net Profit of 365 Million Yuan, Up 6.10%

Stock News08-19

Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) released its 2025 interim report, showing operating revenue of 2.131 billion yuan, representing a year-on-year increase of 4.32%. Net profit attributable to shareholders reached 365 million yuan, up 6.10% compared to the same period last year. Net profit attributable to shareholders excluding non-recurring items was 347 million yuan, an increase of 3.93% year-on-year. Basic earnings per share stood at 0.33 yuan.

During the reporting period, patent and new product sales demonstrated strong volume growth with significant contribution to revenue, becoming the core pillar of the company's performance growth. In the hypertension treatment sector, the company has established a differentiated product portfolio that continues to expand, ranging from Xinlitan (ARB class) and Xinchaouo (ARNI class) to Fulitan® (ARB/CCB combination preparation) and Fuli'an® (ARB/diuretic combination sustained-release preparation), precisely addressing the medication needs of different patient groups.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162375176?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162375176","market":"fut","top_or_hot":-1,"title":"Shenzhen Salubris Pharmaceuticals Reports First Half Results with Net Profit of 365 Million Yuan, Up 6.10%","media":"Stock News","content":"<p>Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) released its 2025 interim report, showing operating revenue of 2.131 billion yuan, representing a year-on-year increase of 4.32%. Net profit attributable to shareholders reached 365 million yuan, up 6.10% compared to the same period last year. Net profit attributable to shareholders excluding non-recurring items was 347 million yuan, an increase of 3.93% year-on-year. Basic earnings per share stood at 0.33 yuan.</p>\n<p>During the reporting period, patent and new product sales demonstrated strong volume growth with significant contribution to revenue, becoming the core pillar of the company's performance growth. In the hypertension treatment sector, the company has established a differentiated product portfolio that continues to expand, ranging from Xinlitan (ARB class) and Xinchaouo (ARNI class) to Fulitan® (ARB/CCB combination preparation) and Fuli'an® (ARB/diuretic combination sustained-release preparation), precisely addressing the medication needs of different patient groups.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Salubris Pharmaceuticals Reports First Half Results with Net Profit of 365 Million Yuan, Up 6.10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Salubris Pharmaceuticals Reports First Half Results with Net Profit of 365 Million Yuan, Up 6.10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-19 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) released its 2025 interim report, showing operating revenue of 2.131 billion yuan, representing a year-on-year increase of 4.32%. Net profit attributable to shareholders reached 365 million yuan, up 6.10% compared to the same period last year. Net profit attributable to shareholders excluding non-recurring items was 347 million yuan, an increase of 3.93% year-on-year. Basic earnings per share stood at 0.33 yuan.</p>\n<p>During the reporting period, patent and new product sales demonstrated strong volume growth with significant contribution to revenue, becoming the core pillar of the company's performance growth. In the hypertension treatment sector, the company has established a differentiated product portfolio that continues to expand, ranging from Xinlitan (ARB class) and Xinchaouo (ARNI class) to Fulitan® (ARB/CCB combination preparation) and Fuli'an® (ARB/diuretic combination sustained-release preparation), precisely addressing the medication needs of different patient groups.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0196","symbol_name":"行业龙头","start_time":0,"source_url":"","article_id":"1162375176","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162375176","pubTimestamp":1755600259,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) released its 2025 interim report, showing operating revenue of 2.131 billion yuan, representing a year-on-year increase of 4.32%. Net profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0196":"行业龙头","BK0187":"一线龙头","002294":"信立泰","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念","BK0188":"融资融券"},"translate_title":"深圳赛鲁布里斯制药公布上半年业绩净利润3.65亿元增长6.10%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002294":1},"content_text":"Shenzhen Salubris Pharmaceuticals Co.,Ltd. (002294.SZ) released its 2025 interim report, showing operating revenue of 2.131 billion yuan, representing a year-on-year increase of 4.32%. Net profit attributable to shareholders reached 365 million yuan, up 6.10% compared to the same period last year. Net profit attributable to shareholders excluding non-recurring items was 347 million yuan, an increase of 3.93% year-on-year. Basic earnings per share stood at 0.33 yuan.\nDuring the reporting period, patent and new product sales demonstrated strong volume growth with significant contribution to revenue, becoming the core pillar of the company's performance growth. In the hypertension treatment sector, the company has established a differentiated product portfolio that continues to expand, ranging from Xinlitan (ARB class) and Xinchaouo (ARNI class) to Fulitan® (ARB/CCB combination preparation) and Fuli'an® (ARB/diuretic combination sustained-release preparation), precisely addressing the medication needs of different patient groups.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162375176","isCrawlerRequest":true}